Cargando…

Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes

Patient: Male, 68 Final Diagnosis: Mesothelioma Symptoms: Dyspnea Medication: — Clinical Procedure: — Specialty: Pulmonology OBJECTIVE: Rare disease BACKGROUND: Malignant pleural mesothelioma (MPM) is a highly lethal cancer with a median survival of ∼12 months even with aggressive intervention. Fron...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Riley G., Karthik, Felix, Dugar, Anushree, Kanagarajan, Karthik, Desai, Kalpan, Bhandari, Manish
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061454/ https://www.ncbi.nlm.nih.gov/pubmed/29970876 http://dx.doi.org/10.12659/AJCR.909584

Ejemplares similares

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
por: Hearon, Bernard F., et al.
Publicado: (2020)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant Deciduoid Mesothelioma: case presentation of an exceptional variant and review of the literature
por: Khmou, Mouna, et al.
Publicado: (2017)

Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma
por: Sakakibara-Konishi, Jun, et al.
Publicado: (2020)

Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series
por: Hashimoto, Kentaro, et al.
Publicado: (2022)

Advances in Immunotherapy of Malignant Pleural Mesothelioma
por: Liao, Dongying, et al.
Publicado: (2021)

Exceptional Responder to Immunotherapy: A Rare Case of Post-HSCT DLBCL Relapse Responding to Nivolumab
por: Madabhavi, Irappa, et al.
Publicado: (2019)

An appropriate choice for immunotherapy in malignant pleural mesothelioma
por: Fujimoto, Nobukazu
Publicado: (2020)

The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
por: Banerji, Shantanu, et al.
Publicado: (2021)

Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
por: Tsubouchi, Kazuya, et al.
Publicado: (2020)

Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy
por: Agrawal, Shruti, et al.
Publicado: (2015)

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
por: Agrawal, Shruti, et al.
Publicado: (2016)

Malignancy during pregnancy in Japan: an exceptional opportunity for early diagnosis
por: Sekine, Masayuki, et al.
Publicado: (2018)

Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations
por: Sejben, Anita, et al.
Publicado: (2023)

Current State of Pleural-Directed Adjuncts Against Malignant Pleural Mesothelioma
por: Choi, Agnes Y., et al.
Publicado: (2022)

Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020)

Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma
por: Gray, Steven G.
Publicado: (2021)

Current status and progress in immunotherapy for malignant pleural mesothelioma
por: Sun, Boyang, et al.
Publicado: (2022)

Editorial: Focus on malignant pleural mesothelioma immunology and immunotherapy
por: Porta, Chiara, et al.
Publicado: (2023)

Highlight: Exceptions Are the Rule in Sex Determination
por: McGrath, Casey
Publicado: (2020)

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
por: Yoneda, Hiroto, et al.
Publicado: (2021)

Abdominal pain as an initial symptom of isolated ACTH deficiency induced by nivolumab in a patient with malignant mesothelioma
por: Hata, Koichi, et al.
Publicado: (2021)

Promising therapeutic potential of tumor suppressor microRNAs for malignant pleural mesothelioma
por: Dixit, Shivani, et al.
Publicado: (2022)

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma
por: Bensaid, Douae, et al.
Publicado: (2018)

Immunotherapy in malignant pleural mesothelioma: a review of literature data
por: Menis, Jessica, et al.
Publicado: (2021)

An exception that proves the rule: recurrence free survival five years after extrapleural pneumonectomy for malignant pleural mesothelioma
por: Treasure, Tom, et al.
Publicado: (2014)

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
por: Minchom, Anna, et al.
Publicado: (2020)

Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program
por: Cantini, Luca, et al.
Publicado: (2020)

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
por: Fujimoto, Nobukazu, et al.
Publicado: (2020)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
por: Gounant, Valérie, et al.
Publicado: (2021)

Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma
por: Meiller, Clément, et al.
Publicado: (2021)

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
por: Yang, Liu, et al.
Publicado: (2022)

Malignant mesothelioma
por: Ruffié, P, et al.
Publicado: (2001)

Malignant mesothelioma
por: Moore, Alastair J, et al.
Publicado: (2008)

Malignant mesothelioma
por: Ahmed, Ishtiaq, et al.
Publicado: (2013)

Malignant Mesothelioma
por: Pouliquen, Daniel L., et al.
Publicado: (2021)

Cytomegalovirus infection in malignant pleural mesothelioma
por: Hunter-Schlichting, DeVon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o3u9o1fopt4b5ff705hs19ujn0